Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial
Open Access
- 16 February 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (4) , 959-967
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. CHIP is more prevalent among people with HIV (PWH), but the risk factors are unknown. CHIP was identified among PWH in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) using whole-exome sequencing. Logistic regression was used to associate sociodemographic factors and HIV-specific factors with CHIP adjusting for age, sex, and smoking status. In the studied global cohort of 4486 PWH, mean age was 49.9 (standard deviation [SD], 6.4) years; 1650 (36.8%) were female; and 3418 (76.2%) were non-White. CHIP was identified in 223 of 4486 (4.97%) and in 38 of 373 (10.2%) among those aged ≥60 years. Age (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.05-1.09; P < .0001) and smoking (OR, 1.37; 95% CI, 1.14-1.66; P < .001) associated with increased odds of CHIP. Globally, participants outside of North America had lower odds of CHIP including sub-Saharan Africa (OR, 0.57; 95% CI, 0.4-0.81; P = .0019), South Asia (OR, 0.45; 95% CI, 0.23-0.80; P = .01), and Latin America/Caribbean (OR, 0.56; 95% CI, 0.34-0.87; P = .014). Hispanic/Latino ethnicity (OR, 0.38; 95% CI, 0.23-0.54; P = .002) associated with significantly lower odds of CHIP. Among HIV-specific factors, CD4 nadir <50 cells/mm3 associated with a 1.9-fold (95%CI, 1.21-3.05; P = .006) increased odds of CHIP, with the effect being significantly stronger among individuals with short duration of antiretroviral therapy (ART; OR, 4.15; 95% CI, 1.51-11.1; P = .005) (Pinteraction= .0492). Among PWH at low-to-moderate CAD risk on stable ART, smoking, CD4 nadir, North American origin, and non-Hispanic ethnicity associated with increased odds of CHIP. This trial was registered at www.ClinicalTrials.gov as NCT02344290.Keywords
This publication has 35 references indexed in Scilit:
- Effect of Clonal Hematopoiesis on Cardiovascular Disease in People Living with HIVExperimental Hematology, 2022
- Cancer therapy shapes the fitness landscape of clonal hematopoiesisNature Genetics, 2020
- Inherited causes of clonal haematopoiesis in 97,691 whole genomesNature, 2020
- Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersAmerican Heart Journal, 2019
- Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)American Heart Journal, 2019
- Analysis of protein-coding genetic variation in 60,706 humansNature, 2016
- Exploring Statins to Decrease HIV-Related Heart Disease RiskJAMA, 2015
- Risk of coronary heart disease in patients with HIV infectionNature Reviews Cardiology, 2014
- HIV Infection and the Risk of Acute Myocardial InfarctionJAMA Internal Medicine, 2013
- CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapyJournal of Clinical Virology, 2012